Supernus Pharmaceuticals, Inc.

NASDAQ:SUPN

Drug Manufacturers - Specialty & Generic

Healthcare
$28.96 +1.17%

+$0.51 today

Market cap
$6.02B
Beta
0.54
P/E (TTM)
-87.6
EPS (TTM)
-$0.50
52W Low $30.83High $59.68

Volume 2.71M

Average 0.64M

SUPN Net Debt

Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.

Supernus Pharmaceuticals, Inc.NASDAQ: SUPN

Net Debt · Q2 FY2026 · quarter ended Jun 2026

Net debt remains negative

Q2 FY2026 net debt was -$139.78M, compared with -$112.94M a year earlier.

Context

  • Net debt amounted to 9.8% of total assets at the end of Q2 FY2026, up 1.6 pp from a year earlier.
  • Net debt increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether net debt keeps falling in the next quarterly balance sheet after a -23.8% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$139.78M+2.9% QoQ
Last fiscal yearDec 2025
-$87.47M-149.5% YoY
Year agoJun 2025
-$112.94M-23.8% since
Net Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-23.8%——
1 year-149.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Debt history

USD · from the balance sheet

Latest · FY2025
(87.47M) USD
Year-over-year change
-149.5%

Net Debt vs competitors

How SUPN compares with its peers on the latest reported figures

  • SUPN's Jun 2026 net debt of -$139.78M is the lowest of the 3 companies compared; the peer median is $739.59M.
  • Its year-over-year change of -23.8% is the 2nd highest of 3, against a peer median of +122.3%.
  • Net debt amounts to 9.8% of total assets for SUPN, versus a peer median of 26.9%.
SUPN Competitors Peer median
Net Debt for SUPN and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ALKSAlkermes plcSep 2026$939.77M +272.5%—21.2%
COLLCollegium Pharmaceutical, Inc.Mar 2026$539.41M -27.9%+8.8%32.7%
SUPNSupernus Pharmaceuticals, Inc.Jun 2026-$139.78M -23.8%—9.8%
Peer median (excluding SUPN) $739.59M+122.3%+8.8%26.9%

Competitors are the stored peer set for SUPN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents203.43M93.12M75.05M69.33M128.45M
Short-term Investments136.25M368.21M179.82M384.28M180.22M
Net Receivables148.93M165.5M144.16M142.08M187.8M
Inventory85.96M91.54M77.41M54.29M82.39M
Other Current Assets015.78M16.68M36.09M65.33M
Total Current Assets601.59M734.15M493.11M686.07M644.18M
Property, Plant & Equipment (Net)16.96M15.17M13.53M11.55M10.53M
Goodwill117.52M117.02M117.02M117.02M124.88M
Intangible Assets784.69M702.46M599.89M521.91M569.46M
Long-term Investments119.17M93.9M16.62M00
Tax Assets000038.35M
Other Non-current Assets49.23M39.81M37.51M31.53M65.25M
Total Non-current Assets1.09B968.36M784.56M682M808.47M
Total Assets1.69B1.7B1.28B1.37B1.45B
Account Payables9.33M10.54M1.96M4.59M2.68M
Short-term Debt0401.97M000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities93.04M54.95M77.08M68.57M98.72M
Total Current Liabilities315.38M687.96M290.2M292.4M338.17M
Long-term Debt379.25M0000
Deferred Tax Liabilities85.36M49.81M24.96M4.96M0
Deferred Revenue (Non-current)00000
Other Non-current Liabilities52.02M42.54M7.8M7.6M22.4M
Total Non-current Liabilities557.92M128.35M65.96M39.94M52.76M
Total Liabilities873.3M816.3M356.16M332.34M390.93M
Common Stock53K54K55K56K57K
Retained Earnings379.92M481.25M482.56M556.43M517.88M
Accumulated OCI1.54M(3.21M)(593K)(189K)(44K)
Other Stockholders Equity00000
Minority Interest00000
Total Equity815.85M886.2M921.52M1.04B1.06B
Total Debt427.03M444.76M41.53M34.27M40.98M
Net Debt223.59M351.64M(33.53M)(35.06M)(87.47M)

Supernus Pharmaceuticals, Inc.

NASDAQ:SUPN

Intrinsic Alpha fair value

Locked

Current Price

$28.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.